Observational study / 2010
High soy isoflavone intake was linked to a lower risk of breast cancer recurrence in postmenopausal patients on adjuvant endocrine therapy.
Researchers examined associations between baseline dietary intake of soy isoflavones, assessed via a food frequency questionnaire, and breast cancer recurrence and death among 524 patients over a median follow-up of 5.1 years. Among premenopausal patients, overall death rate was not related to soy isoflavone intake (HR 1.05, 95% CI 0.78-1.71 for >42.3 mg/day vs. <15.2 mg/day, p for trend = 0.87). In postmenopausal patients, the highest quartile of intake had a significantly lower risk of recurrence compared to the lowest quartile (HR 0.67, 95% CI 0.54-0.85, p for trend = 0.02), with inverse associations observed in estrogen and progesterone receptor-positive patients and those receiving anastrozole.
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 524 patients who underwent surgery for breast cancer and were receiving adjuvant endocrine therapy
- What was measured
- Recurrence of breast cancer and death
THE PAPER
Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy.
Kang X, Zhang Q, Wang S, Huang X, Jin S. CMAJ, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.